TY - JOUR
T1 - Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis
AU - Mitsuhashi, Kei
AU - Nosho, Katsuhiko
AU - Sukawa, Yasutaka
AU - Matsunaga, Yasutaka
AU - Ito, Miki
AU - Kurihara, Hiroyoshi
AU - Kanno, Shinichi
AU - Igarashi, Hisayoshi
AU - Naito, Takafumi
AU - Adachi, Yasushi
AU - Tachibana, Mami
AU - Tanuma, Tokuma
AU - Maguchi, Hiroyuki
AU - Shinohara, Toshiya
AU - Hasegawa, Tadashi
AU - Imamura, Masafumi
AU - Kimura, Yasutoshi
AU - Hirata, Koichi
AU - Maruyama, Reo
AU - Suzuki, Hiromu
AU - Imai, Kohzoh
AU - Yamamoto, Hiroyuki
AU - Shinomura, Yasuhisa
PY - 2015
Y1 - 2015
N2 - Recently, bacterial infection causing periodontal disease has attracted considerable attention as a risk factor for pancreatic cancer. Fusobacterium species is an oral bacterial group of the human microbiome. Some evidence suggests that Fusobacterium species promote colorectal cancer development; however, no previous studies have reported the association between Fusobacterium species and pancreatic cancer. Therefore, we examined whether Fusobacterium species exist in pancreatic cancer tissue. Using a database of 283 patients with pancreatic ductal adenocarcinoma (PDAC), we tested cancer tissue specimens for Fusobacterium species. We also tested the specimens for KRAS, NRAS, BRAF and PIK3CA mutations and measured microRNA-21 and microRNA-31. In addition, we assessed epigenetic alterations, including CpG island methylator phenotype (CIMP). Our data showed an 8.8% detection rate of Fusobacterium species in pancreatic cancers; however, tumor Fusobacterium status was not associated with any clinical and molecular features. In contrast, in multivariate Cox regression analysis, compared with the Fusobacterium species-negative group, we observed significantly higher cancer-specific mortality rates in the positive group (p = 0.023). In conclusion, Fusobacterium species were detected in pancreatic cancer tissue. Tumor Fusobacterium species status is independently associated with a worse prognosis of pancreatic cancer, suggesting that Fusobacterium species may be a prognostic biomarker of pancreatic cancer.
AB - Recently, bacterial infection causing periodontal disease has attracted considerable attention as a risk factor for pancreatic cancer. Fusobacterium species is an oral bacterial group of the human microbiome. Some evidence suggests that Fusobacterium species promote colorectal cancer development; however, no previous studies have reported the association between Fusobacterium species and pancreatic cancer. Therefore, we examined whether Fusobacterium species exist in pancreatic cancer tissue. Using a database of 283 patients with pancreatic ductal adenocarcinoma (PDAC), we tested cancer tissue specimens for Fusobacterium species. We also tested the specimens for KRAS, NRAS, BRAF and PIK3CA mutations and measured microRNA-21 and microRNA-31. In addition, we assessed epigenetic alterations, including CpG island methylator phenotype (CIMP). Our data showed an 8.8% detection rate of Fusobacterium species in pancreatic cancers; however, tumor Fusobacterium status was not associated with any clinical and molecular features. In contrast, in multivariate Cox regression analysis, compared with the Fusobacterium species-negative group, we observed significantly higher cancer-specific mortality rates in the positive group (p = 0.023). In conclusion, Fusobacterium species were detected in pancreatic cancer tissue. Tumor Fusobacterium species status is independently associated with a worse prognosis of pancreatic cancer, suggesting that Fusobacterium species may be a prognostic biomarker of pancreatic cancer.
KW - Fusobacterium
KW - MiR-31
KW - Microbiota
KW - Pancreas
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=84927138939&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84927138939&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.3109
DO - 10.18632/oncotarget.3109
M3 - Article
C2 - 25797243
AN - SCOPUS:84927138939
SN - 1949-2553
VL - 6
SP - 7209
EP - 7220
JO - Oncotarget
JF - Oncotarget
IS - 9
ER -